A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Inclusion Criteria:

• Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
• Hemoglobin A1c (HbA1c) of less than or equal to (≤) 10% within 2 months prior to Day 1
• Macular thickening secondary to diabetic macular edema (DME) involving the center ofthe fovea
• Decreased visual acuity attributable primarily to DME
• Ability and willingness to undertake all scheduled visits and assessments
• For women of childbearing potential: agreement to remain abstinent or use acceptablecontraceptive methods that result in a failure rate of <1% per year during thetreatment period and for at least 3 months after the final dose of study treatment

Exclusion Criteria:

• Currently untreated diabetes mellitus or previously untreated patients who initiatedoral or injectable anti-diabetic medication within 3 months prior to Day 1
• Uncontrolled blood pressure, defined as a systolic value greater than (>)180millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is atrest
• Currently pregnant or breastfeeding, or intend to become pregnant during the study
• Treatment with panretinal photocoagulation or macular laser within 3 months prior toDay 1 to the study eye
• Any intraocular or periocular corticosteroid treatment within the past 6 months priorto Day 1 to the study eye
• Prior administration of IVT faricimab in either eye
• Active intraocular or periocular infection or active intraocular inflammation in thestudy eye
• Any current or history of ocular disease other than DME that may confound assessmentof the macula or affect central vision in the study eye
• Any current ocular condition which, in the opinion of the investigator, is currentlycausing or could be expected to contribute to irreversible vision loss due to a causeother than DME in the study eye
• Other protocol-specified inclusion/exclusion criteria may apply